2Barone I,Cui Y,Herynk MH,et al.Expression of the K303R estrogen receptor-a breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.Cancer Res,2009,69(11):4724-4732.
3Fuqua SA,Wiltschke C,Zhang QX,et al.A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.Cancer Res,2000,60(15):4026-4029.
4Zilli M,Grassadonia A,Tinari N,et al.Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.Biochim Biophys Acta,2009,1795(1):62-81.
5Macedo LF,Sabnis G,Brodie A.Aromatase inhibitors and breast cancer.Ann N Y Acad Sci.2009,1151:162-173.
6Brodie A,Jelovac D,Sabnis G,et al.Model systems:mechanisms involved in the loss of sensitivity to letrosole.J Steroid Biochem Mol Biol,2005,95(1-5):41-48.
7Wang X,Masri S,Phung S,et al.The role of amphiregulin in exemestane-resistant breast cancer cells:evidence of an autocrine loopCancer.Cancer Res,2008,68(7):2259-2265.
8Sikora MJ,Cordero KE,Larios JM,et al.The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor:implications for aromatase inhibitor resistance.Breast Cancer Res Treat,2009,115(2):289-296.
9Hiscox S,Davies EL,Lee PB,et al.Aromatase inhibitors in breast cancer.Maturitas,2009,63:275-279.
10Massarweh S,Osborne CK,Jiang S,et al.Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive,HER-2/neu-positive breast cancer.Cancer Res,2006,66:8266-8273.
